Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 1,201–1,300 of 2,517
Park, Y. R., Kim, Y., Lee, H. Y., Lee, G. E., Lee, G. E., Lee, J.-E., & Kim, Y. (2018) · Obstetrics & Gynecology Science · doi:10.5468/ogs.2018.61.3.328 · Cited by 31
“have been found at the R175, G245, R428, R273, and R282 domains [1,2].”
BackgroundFinianos, A. N., Matar, C. F., & Taher, A. T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124070 · Cited by 32
“These byproducts can cause direct chromosomal damage by inducing strand breaks and lead to chromosomal instability and subsequently mutations that could be tumor promoting [49,62,63]; one of which is p53 mutation which is frequently seen in HCC patients [64,65] but also in cancer-free patients with hemochromatosis [66…”
BackgroundVariable Mutations at the p53-R273 Oncogenic Hotspot Position Leads to Altered Properties
Garg, A., Hazra, J. P., Sannigrahi, M. K., Rakshit, S., & Sinha, S. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.12.015 · Cited by 32
Follow the Mutations: Toward Class-Specific, Small-Molecule Reactivation of p53
Loh, S. N. (2020) · Biomolecules · doi:10.3390/biom10020303 · Cited by 30
“To that end, the solution of the X-ray crystal structure of DBD in 1994 [10] and almost three decades of subsequent biophysical and biochemical analysis have defined some of the primary mechanisms by which the hot-spot mutations cause p53 to lose function (vide infra).”
BackgroundTong, X., Xu, D., Mishra, R. K., Jones, R., Sun, L., Schiltz, G. E., Liao, J., & Yang, G. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014749 · Cited by 33
“The conformational mutants, for example, R175H and R249S, change the structure of p53 protein (6), whereas the contact site mutants, such as R248W and R273H, have an altered residue at a site that directly contacts DNA in the wildtype p53 (wtp53) protein (6, 7).”
BackgroundZhang, Y., Huang, X., Wang, L., Cao, C., Zhang, H., Wei, P., Ding, H., Song, Y., Chen, Z., Qian, J., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120720 · Cited by 32
Germline mutations of TP53 gene in breast cancer
Damineni, S., Rao, V. R., Kumar, S., Ravuri, R. R., Kagitha, S., Dunna, N. R., Digumarthi, R., & Satti, V. (2014) · Tumor Biology · doi:10.1007/s13277-014-2176-6 · Cited by 29
Scotcher, J., Clarke, D. J., Mackay, C. L., Hupp, T. R., Sadler, P. J., & Langridge‐Smith, P. R. R. (2013) · Chemical Science · doi:10.1039/c2sc21702c · Cited by 32
Possible association of thioredoxin and p53 in breast cancer
Ueno, M., Matsutani, Y., Nakamura, H., Masutani, H., Yagi, M., Yamashiro, H., Kato, H., Inamoto, T., Yamauchi, A., Takahashi, R., et al. (2000) · Immunology Letters · doi:10.1016/s0165-2478(00)00284-4 · Cited by 30
Ahn, J., Poyurovsky, M. V., Baptiste, N., Beckerman, R., Cain, C. R., Mattia, M., McKinney, K. M., Zhou, J., Zupnick, A., Gottifredi, V., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.10.8548 · Cited by 33
Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma
Feuerborn, A., Möritz, C., von Bonin, F., Dobbelstein, M., Trümper, L. H. P., Stürzenhofecker, B., & Kube, D. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600667721 · Cited by 30
“This loop includes highly conserved amino acid residues and establishes contact of the wild-type p53 protein with the major groove of genomic DNA [20].”
BackgroundKang, J. H., Kim, S. J., Noh, D., et al. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100269 · Cited by 30
“a Domain for L2 and L3: 163–195 and 236–251 [7] b Region for direct DNA contact: 120, 241, 248, 273, 276, 280, 283 [7] c Highly conserved region, evolutionarily: II: 117–142, III: 171–181, IV: 234–258, V: 270–286 [4] d Student’s t test”
BackgroundGenetic predisposition to breast cancer: a surgical perspective
Sakorafas, G. H., & Tsiotou, A. G. (2000) · British journal of surgery · doi:10.1046/j.1365-2168.2000.01347.x · Cited by 39
Qi, J.-S., Desai-Yajnik, V., Yuan, Y., & Samuels, H. H. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.12.7195 · Cited by 30
“Human 293T cells were transfected with pEBG or pEBG-cT3Ra(1-408) as”
BackgroundMethodInfluentialDietary fiber and plant foods in relation to colorectal cancer mortality: The Seven Countries Study
Jansen, M. C. J. F., Bueno‐de‐Mesquita, H. B., Buzina, R., Fidanza, F., Menotti, A., Blackburn, H., Nissinen, A. M., Kok, F. J., & Kromhout, D. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990412)81:2<174::aid-ijc2>3.0.co;2-# · Cited by 95
Mutation Spectra Resulting from Carcinogenic Exposure: From Model Systems to Cancer-Related Genes
Dogliotti, E., Hainaut, P. L., Hernandez‐Boussard, T., D’Errico, M., & DeMarini, D. M. (1998) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-46870-4_6 · Cited by 32
p53 Abnormalities in hepatocellular carcinoma from United States patients: analysis of all 11 exons
Kazachkov, Y., Khaoustov, V. I., Yoffe, B., et al. (1996) · Carcinogenesis · doi:10.1093/carcin/17.10.2207 · Cited by 30
Chen, Y., Chen, P., & Lee, W. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.10.6764 · Cited by 38
Liu, N., Jiang, X., Guo, L., Zhang, C., Jiang, M., Sun, Z., Zhang, Y., Mi, W., Li, J., Fu, Y., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.67200 · Cited by 33
“The mutant p53 can be divided into nonsense, frameshift, splice site, indel, missense, and other types [2].”
BackgroundOne-Dimensional Search Dynamics of Tumor Suppressor p53 Regulated by a Disordered C-Terminal Domain
Murata, A., Itoh, Y., Mano, E., Kanbayashi, S., Igarashi, C., Takahashi, H., Takahashi, S., & Kamagata, K. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.04.038 · Cited by 29
Shen, T., Li, S., Wang, J., Zhang, T., Zhang, S., Chen, H., Xiao, Q., Ren, W., Liu, C., Peng, B., et al. (2020) · Liver International · doi:10.1111/liv.14581 · Cited by 36
Qian, J., Zhang, W., Wei, P., Yao, G., Yi, T., Zhang, H., Ding, H., Huang, X., Wang, M., Song, Y., et al. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202001994 · Cited by 30
Gilleran, J., Yu, X., Blayney, A. J., Bencivenga, A. F., Na, B., Augeri, D. J., Blanden, A. R., Kimball, S. D., Loh, S. N., Roberge, J. Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01360 · Cited by 29
Modelling the interaction between the p53 DNA‐binding domain and the p28 peptide fragment of Azurin
Santini, S., Bizzarri, A. R., & Cannistraro, S. (2011) · Journal of Molecular Recognition · doi:10.1002/jmr.1153 · Cited by 29
“The DBD structure of p53 used in the docking procedure was derived from chain B of the Protein Data Bank (PDB) entry 1TUP (Figure 1), which provides a 2.2-Å resolution crystal structure of this domain complexed with a consensus DNA (Cho et al., 1994).”
BackgroundMethodInfluentialDesign and synthesis of 8-hydroxyquinoline-based radioprotective agents
Ariyasu, S., Sawa, A., Morita, A., Hanaya, K., Hoshi, M., Takahashi, I., Wang, B., & Aoki, S. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.06.017 · Cited by 29
RepEx: Repeat extractor for biological sequences
Gurusaran, M., Ravella, D., & Sekar, K. (2013) · Genomics · doi:10.1016/j.ygeno.2013.07.005 · Cited by 28
“0 GHz Intel Core 2 Duo processor and 8 GB RAM), one of which (LTIITL) is known to localize in the DNA binding domain of the protein [27].”
BackgroundThe screening of the second‐site suppressor mutations of the common p53 mutants
Otsuka, K., Kato, S., Kakudo, Y., Mashiko, S., Shibata, H., & Ishioka, C. (2007) · International Journal of Cancer · doi:10.1002/ijc.22724 · Cited by 23
“The structure of the core DNA-binding domain has been resolved by X-ray crystallographic analysis.(2) The p53 forms a homotetramer through the tetramerization domain and the p53 tetramer forms a sequence-specific DNA-binding interface.”
MethodA novel p53 mutant retained functional activity in lung carcinomas
Ko, J., Chiao, M.-C., Chang, S.-L., Lin, P., Lin, J.-C., Gwo-Tarng, S., & Lee, H. (2002) · DNA repair · doi:10.1016/s1568-7864(02)00094-0 · Cited by 31
Identification of a tumor-derived p53 mutant with novel transactivating selectivity
Pan, Y., & Haines, D. S. (2000) · Oncogene · doi:10.1038/sj.onc.1203663 · Cited by 32
“The majority of tumor derived p53 mutants harbor amino acid changes in the DNA binding domain (Cho et al., 1994) and many mutants are unable to bind to speci®c promoter elements (el-Deiry et al., 1992; Funk et al., 1992).”
BackgroundiASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition
Chen, S., Wu, J., Zhong, S., Li, Y., Zhang, P., Ma, J., Ren, J., Tan, Y., Wang, Y., Au, K. F., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909393116 · Cited by 30
“These mutations have been thought to destabilize p53 DBD structure thereby disrupting its function (19).”
Influentialp53 Alterations in Colon Tumors
Curtin, K. P., Slattery, M. L., Holubkov, R., Edwards, S. L., Holden, J. A., & Samowitz, W. S. (2004) · Applied immunohistochemistry & molecular morphology · doi:10.1097/00129039-200412000-00017 · Cited by 29
Kok, S., Hong, C., Lin, S., et al. (2006) · Oral Oncology · doi:10.1016/j.oraloncology.2006.07.007 · Cited by 29
Fleckenstein, D., Uphoff, C. C., Drexler, H. G., & Quentmeier, H. (2002) · Leukemia Research · doi:10.1016/s0145-2126(01)00107-2 · Cited by 30
“Mutation at this site destabilizes the tertiary structure of p53, resulting in loss of DNA binding and tumor suppressor function [7,8].”
BackgroundNovel patterns of p53 abnormality in breast cancer from Taiwan: experience from a low-incidence area
Lou, M. A. A., Tseng, S.-L., Chang, S., Yue, C., Chang, B., Chou, C.-H., Yang, S., Teh, B.-H., Wu, C., & Shen, C. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.132 · Cited by 31
“Current evidence of the structure-function relationship of p53 (Cho et al, 1994) suggests that some mutants of p53 alter their function and confer upon cells a growth advantage.”
BackgroundOverexpression of bax Associated with Mutations in the Loop-Sheet-Helix Motif of p53
Huang, C., Kohno, N., Inufusa, H., Kodama, K., Taki, T., & Miyake, M. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65195-4 · Cited by 29
“This variation in pattern of bax expression in relation to mutant p53 might reflect the biological behavior of tumors in patients with bcl-2positive NSCLC. (Am J Pathol 1999, 155:955–965) p53 is one of the major tumor suppressor genes,1–4 and most nonfunctioning p53 proteins with missense mutations of one p53 allele c…”
BackgroundMa, B., Pan, Y., Gunasekaran, K., Venkataraghavan, R. B., Levine, A. J., & Nussinov, R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500215102 · Cited by 29
Non-p53 p53RE binding protein, a human transcription factor functionally analogous to P53
Zeng, X., Levine, A. J., & Lu, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6681 · Cited by 33
p53 Differentially Inhibits Cell Growth Depending on the Mechanism of Telomere Maintenance
Razak, Z. R. A., Varkonyi, R. J., McEliece, M. K., Caslini, C., Testa, J. R., Murphy, M. E., & Broccoli, D. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.13.5967-5977.2004 · Cited by 34
“To directly test if the transactivation-independent, ALT-specific growth inhibition is due to interference with recombination-based telomere maintenance, we introduced into the ts-p53TA plasmid the R175H, R248Q, and R273H mutations, which compromise the specific DNA binding and suppression of recombination functions o…”
BackgroundHayes, V. M., Bleeker, W. A., Verlind, E., et al. (1999) · Diagnostic Molecular Pathology · doi:10.1097/00019606-199903000-00002 · Cited by 29
Kunz, M., Toksoy, A., Goebeler, M., Engelhardt, E., Br�cker, E.-B., & Gillitzer, R. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199912)189:4<552::aid-path469>3.0.co;2-i · Cited by 139
PAK1, a gene that can regulate p53 activity in yeast.
Thiagalingam, S., Kinzler, K. W., & Vogelstein, B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.13.6062 · Cited by 29
Identification of a Region of p53 That Confers Lability
Li, X., & Coffino, P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4447 · Cited by 28
Suzuki, M., & Brenner, S. E. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00988-l · Cited by 35
p53 latency – out of the blind alley
Yakovleva, T., Pramanik, A., Terenius, L. Y., Ekström, T., & Bakalkin, G. Y. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02209-0 · Cited by 31
Binkley, J., Karra, K., Kirby, A. W., Hosobuchi, M., Stone, E. A., & Sidow, A. (2009) · Genome Research · doi:10.1101/gr.097121.109 · Cited by 33
“The following URL initiates a ProPhylER session for the heterodimeric transcription factor E2F–DP bound to DNA (Zheng et al. 1999), which illustrates the functionality of the CrystalPainter (http://www.prophyler.org/ cgi-bin/example2.cgi).”
BackgroundInfluentialThangavelu, L. P., Altamimi, A. S., Ghaboura, N., Babu, M. A., Roopashree, R., Sharma, P., Pal, P., Choudhary, C., Prasad, G. V. S., Sinha, A., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155652 · Cited by 35
R248Q mutation—Beyond p53‐DNA binding
Ng, J. W. K., Lama, D., Lukman, S., Lane, D. P., Verma, C. S., & Sim, A. Y. L. (2015) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.24940 · Cited by 28
Human pregnane X receptor compromises the function of p53 and promotes malignant transformation
Robbins, D. F., Cherian, M. T., Wu, J., & Chen, T. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.23 · Cited by 28
Subekti, D. R. G., Murata, A., Itoh, Y., Fukuchi, S., Takahashi, H., Kanbayashi, S., Takahashi, S., & Kamagata, K. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00292 · Cited by 41
Mitra, N., & Dey, S. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.108226 · Cited by 30
Singh, J., Luqman, S., & Meena, A. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111592 · Cited by 33
Timmerman, D. M., Remmers, T. L., Hillenius, S., & Looijenga, L. H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105377 · Cited by 28
“An example of a hotspot mutations is an SNP at residue 175 where arginine is substituted by a histidine (R175H), which occurs in approximately 4–5% of all tumors and has been shown to impair the folding of the P53 protein [65,66].”
BackgroundInfluentialSystematic review and meta‐analysis of genomic alterations in acral melanoma
Broit, N., Johansson, P. A., Rodgers, C. B., Walpole, S., Hayward, N. K., & Pritchard, A. L. (2022) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13034 · Cited by 29
“R273C: n = 707 in somatic IARC TP53 database) and are classified as “contact” mutations, for which the overall architecture of the DNA binding domain is retained, but there is loss of critical DNA contact (Cho et al., 1994; Olivier et al., 2010).”
The Development of p53-Targeted Therapies for Human Cancers
Lu, Y., Wu, M. Y., Xu, Y., & Yu, L. (2023) · Cancers · doi:10.3390/cancers15143560 · Cited by 32
“Zinc is essential for the correct folding of the central core domain of p53, and the absence of a zinc molecule in the central core can cause p53 to unfold and aggregate [59,60].”
BackgroundHoffman-Luca, C. G., Yang, C.-Y., Lu, J., Ziazadeh, D., McEachern, D., Debussche, L., & Wang, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128807 · Cited by 28
“In the crystal structure of wildtype p53 in a complex with DNA (PDBID: 4HEJ) [32], C176, together with H179, C238, C242 residues, coordinates with a zinc ion and appears to be very critical in maintaining the structural integrity of p53 [40,41].”
BackgroundZn(II)-curc targets p53 in thyroid cancer cells
Garufi, A., D’Orazi, V., Crispini, A., & D’Orazi, G. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3125 · Cited by 29
“The rationale to use Zn(II) comes from the fact that p53 protein includes one zinc ion (Zn2+) as an important cofactor for the proper protein folding to efficiently bind the DNA of sequence-specific target genes (23).”
A Tale of Chromatin and Transcription in 100 Structures
Cramer, P. (2014) · Cell · doi:10.1016/j.cell.2014.10.047 · Cited by 30
“, 1994) and a DNA-binding domain that harbors tumorigenic mutations that can impair DNA binding (Cho et al., 1994).”
Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53
Dixit, U., Liu, Z., Pandey, A. K., Kothari, R. K., & Pandey, V. N. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-925 · Cited by 29
“In Huh7 cells p53 contains an Y220C mutation that is located outside of the conserved p53-DNA binding domain and therefore not essential for the tertiary structure of the DNA binding surface [25,35].”
BackgroundRegulating apoptosis in mammalian cell cultures
Arden, N., & Betenbaugh, M. J. (2006) · Cytotechnology · doi:10.1007/s10616-006-9008-5 · Cited by 33
“Upon upregulation, p53 becomes stabilized and acts as a transcription factor for many genes, binding to consensus sequences found on DNA with its central core domain of 200 amino acids ( Cho et al. 1994 ).”
BackgroundJessen-Eller, K., Kreiling, J. A., Begley, G. S., Steele, M. E., Walker, C. W., Stephens, R. E., & Reinisch, C. L. (2002) · Environmental Health Perspectives · doi:10.1289/ehp.02110377 · Cited by 29
“Amino acids that help maintain the structure of the DNA-binding domain and coordinate the zinc atom (32) are the same in all molluscan and vertebrate p53 homologues.”
BackgroundKim, Y., Kim, J., Lee, H. D., Jeong, J., Lee, W., & Lee, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079014 · Cited by 28
“In addition, missense mutations were further subdivided as missense mutations in DNA binding motifs (DBM) and outside the DBM according to mutation position, nature, and suspected effect on protein structure and activity [23,35].”
BackgroundKrüger, A., Stier, A., Fischbach, A., Bürkle, A., Hauser, K., & Mangerich, A. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz175 · Cited by 32
“A loop-sheet-helix motif and two loops form the DNA binding surface (16,17).”
Abrogation of FBW7α-dependent p53 degradation enhances p53’s function as a tumor suppressor
Tripathi, V., Kaur, E., Kharat, S. S., Hussain, M., Damodaran, A. P., Kulshrestha, S., & Sengupta, S. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.008483 · Cited by 30
Evaluation of transcriptional activity of p53 in individual living mammalian cells
Imagawa, T., Terai, T., Yamada, Y., Kamada, R., & Sakaguchi, K. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.01.030 · Cited by 36
Avivi, A., Ashur‐Fabian, O., Amariglio, N., Nevo, E., & Rechavi, G. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1534 · Cited by 31
Glazko, G. V., Koonin, E. V., & Rogozin, I. B. (2004) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/j.bbaexp.2004.05.004 · Cited by 35
Klumb, C. E., Furtado, D. R., de Resende, L. M. M., Carriço, M. K., Coelho, A. M., de Meis, E., Maia, R. C., & Rumjanek, F. D. (2003) · European Journal Of Haematology · doi:10.1034/j.1600-0609.2003.00094.x · Cited by 31
“in 1991 (37), two classes of mutations were described.”
BackgroundMigliavacca, M., Ottini, L., Bazan, V., et al. (2004) · Journal of Cellular Physiology · doi:10.1002/jcp.20053 · Cited by 28
“…with a great many functional domains, among which the L2 loop, which is needed for the correct folding and stabilization of the central part of the protein, the L3 loop and the L1 loop-sheet-helix motif (LSH), directly involved in interaction between the protein and the DNA (Cho et al., 1994).”
BackgroundBlagosklonny, M. V., Giannakakou, P., Romanova, L. Y., Ryan, K. M., Vousden, K. H., & Fojo, T. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.861 · Cited by 30
Russo, A. D., Migliavacca, M., Zanna, I., et al. (2002) · PubMed · Cited by 28
Almog, N., Li, R., Peled, A., Schwartz, D., Wolkowicz, R., Goldfinger, N., Pei, H., & Rotter, V. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.2.713 · Cited by 30
“The central part of the molecule was shown to interact with the p53-specific sequences contained within downstream p53 target genes (4, 7, 51, 72).”
BackgroundTargeting gene expression to tumor cells with loss of wild-type p53 function
Zhu, J., Gao, B., Zhao, J., & Balmain, A. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700091 · Cited by 26
Transcriptional Regulation by p53
Hsu, Y.-S., Tang, F.-M., Liu, W., Chuang, J., Lai, M., & Lin, Y.-S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.12.6966 · Cited by 30
D’Orazi, G., & Givol, D. (2012) · Cell Cycle · doi:10.4161/cc.21020 · Cited by 28
Discussion of some ‘knowns’ and some ‘unknowns’ about the tumour suppressor p53
Lieschke, E., Wang, Z., Kelly, G. L., & Strasser, A. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy077 · Cited by 30
“Conversely, the so-called contact mutants have a structure that is similar to that of wild-type p53 and only differ in one amino acid that contacts DNA in the regulatory sequences of target genes (Cho et al., 1994; Muller and Vousden, 2014).”
BackgroundEibl, J. K., Abdallah, Z., & Ross, G. M. (2010) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y10-022 · Cited by 30
TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.
Zheng, H., Wang, Y., Tang, C., Jones, L. E., Ye, H., Zhang, G., Cao, W., Li, J., Liu, L., Liu, Z., et al. (2016) · PubMed · Cited by 29
p53: Multiple Facets of a Rubik's Cube
Zhang, Y., & Lozano, G. (2016) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-121926 · Cited by 28
Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms
Patel, U., Luthra, R., Medeiros, L. J., & Patel, K. P. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.015 · Cited by 26
“p53 binds directly to DNA and determines whether the cell undergoes repair, senescence, or apoptosis in response to cellular stress or damage.(94) Most TP53 mutations in cancers occur in the DNA binding domain in exons 5 to 8.”
BackgroundSalvation of the fallen angel: Reactivating mutant p53
Yang, L., Wang, Z., Chen, Y., Petersen, R. B., Zheng, L., & Huang, K. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14572 · Cited by 28
Paul, S., Patra, D., & Kundu, R. (2019) · Scientific Reports · doi:10.1038/s41598-019-51480-7 · Cited by 28
Kaushik, A. C., Wang, Y., Wang, X., & Wei, D. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa149 · Cited by 28
Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry
Khadiullina, R., Mirgayazova, R., Davletshin, D., Khusainova, E., Chasov, V. V., & Bulatov, E. (2022) · Life · doi:10.3390/life13010031 · Cited by 31
“The locations of amino acids R175, Y220, G245, R248, R249, R273 and R282, which are sites of key carcinogenic mutations (“hot spots”), are shown (PDB identifier: 1TSR) [4].”
BackgroundInfluentialDuan, W., Gao, L., Wu, X., Wang, L., Nana-Sinkam, S. P., Otterson, G. A., & Villalona-Calero, M. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.25049 · Cited by 28
“As a result, mutant p53 proteins are unable to bind to and transactivate the target genes that mediate tumor suppression.(6,7) By providing a key difference between normal cells and tumor cells, the p53 protein represents an important target for drug development.”
BackgroundAugello, C., Gregorio, V., Bazan, V., Cammareri, P., Agnese, V., Cascio, S., Corsale, S., Calò, V., Gullo, A., Passantino, R., et al. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20601 · Cited by 29
Fleischhacker, A. S., Carter, E. L., & Ragsdale, S. W. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7368 · Cited by 27
“Significantly, NPAS2 is also a hemoprotein that binds carbon monoxide (CO), which further regulates its DNA-binding activity (17).”
BackgroundInfluentialGodfrey, J. D., Morton, J. P., Wilczynska, A., Sansom, O. J., & Bushell, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0628-4 · Cited by 29
Ma, J., Fu, Y., Tu, Y.-Y., Liu, Y., Tan, Y.-R., Ju, W., Pickering, C. R., Myers, J. N., Zhang, Z.-Y., & Zhong, L.-P. (2018) · BMC Cancer · doi:10.1186/s12885-018-4481-8 · Cited by 28
The Tip of an Iceberg: Replication-Associated Functions of the Tumor Suppressor p53
Gottifredi, V., & Wiesmüller, L. (2018) · Cancers · doi:10.3390/cancers10080250 · Cited by 30
“Since then a wide range of p53 target genes has been described covering all thinkable biological functions ranging from metabolism to DNA repair [2,3].”
BackgroundThe Essential Transfer Protein TraM Binds to DNA as a Tetramer
Verdino, P., Keller, W. D., Strohmaier, H. M., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.52.37421 · Cited by 27
Siddiqi, M., Aga, S. S., Rehman, S. U., Pandith, A., Syeed, N., Shah, Z. A., Chowdhri, N., & Wani, K. A. (2009) · Saudi Journal of Gastroenterology · doi:10.4103/1319-3767.56102 · Cited by 27
Kaneko, K., Katagiri, A., Konishi, K., Kurahashi, T., Ito, H., Kumekawa, Y., Yamamoto, T., Muramoto, T., Kubota, Y., Nozawa, H., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603582 · Cited by 28
“A hotspot can identify a relationship between the mutation, protein structure and function, and carcinogenesis (Hsu et al, 1991; Cho et al, 1994; Greenblatt et al, 1994; Tornaletti and Pfeifer, 1994).”
BackgroundGene‐specific mechanisms of p53 transcriptional control and prospects for cancer therapy
Resnick‐Silverman, L., & Manfredi, J. J. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20925 · Cited by 30
“As the list of p53-regulated genes continues to grow, so does the possibility of other as yet undefined biologic responses. structure that has defined the contact points of this conserved domain with the major and minor grooves of a cognate site [Cho et al., 1994].”
BackgroundEmamzadah, S., Petty, T. J., Almeida, V. D., et al. (2009) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909021489 · Cited by 27
“The latter two domains are independently folding domains and their three-dimensional structures have been determined (Cho et al., 1994; Jeffrey et al., 1995); however, no structure is available of a p53 polypeptide containing both of these domains.”
BackgroundMicrosatellite Instability and p53 Mutations in Hepatocellular Carcinoma
Karachristos, A., Liloglou, T., Field, J. K., et al. (1999) · Molecular Cell Biology Research Communications · doi:10.1006/mcbr.1999.0170 · Cited by 27
Homogeneous amplification and mutation scanning of the p53 gene using fluorescent melting curves.
Millward, H., Samowitz, W., Wittwer, C., & Bernard, P. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.8.1321 · Cited by 29
“From the 11 exons, the first being noncoding, exons 5–8 (codons 102–292) encode the DNAbinding domain (5, 6).”
BackgroundFunctional dissection of p53 tumor suppressor protein
Jayaraman, L., Freulich, E., & Prives, C. L. (1997) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(97)83020-0 · Cited by 31
Semenza, J. C., & Weasel, L. H. (1997) · Environmental Health Perspectives · doi:10.1289/ehp.97105s1155 · Cited by 31
In vitro evolution of thermostable p53 variants
Matsumura, I., & Ellington, A. D. (1999) · Protein Science · doi:10.1110/ps.8.4.731 · Cited by 27
“9A; Cho et al., 1994!, and rationalized in terms of their contributions to structure, stability, and function.”
BackgroundMutant p53 expression: a marker of diminished survival in well-differentiated soft tissue sarcoma.
Hieken, T. J., & Gupta, T. K. D. (1996) · PubMed · Cited by 27
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.